CD2-HM123B-100μg / 询价
CD2-HM123B-100μg x 5 / 询价
CD2-HM123B-100μg x 10 / 询价
- 客服电话
- 技术支持
Biotinylated Human CD20 Protein-VLP
Recombinant Biotinylated Human CD20 Protein-VLP is expressed from HEK293.It contains Met1-Pro297 [Accession | P11836-1].
The target protein has a predicted MW of 34.3 kDa.
> 95% as determined by HPLC
Less than 1EU per μg by the LAL method.
Supplied as 0.22μm filtered solution in PBS, 300mM L-Arginine (pH 7.4).
Valid for 12 months from date of receipt when stored at -80°C.
Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
The purity of Biotinylated Human CD20 VLP is greater than 95% as determined by SEC-HPLC.
Immobilized Biotinylated Human CD20 VLP at 5μg/ml (100μl/well) on the streptavidin precoated plate (5μg/ml). Dose response curve for Rituximab, hFc Tag with the EC50 of 14.7ng/ml determined by ELISA (QC Test).
Biotinylated Human CD20 VLP captured on CM5 Chip via streptavidin can bind Rituximab, hFc Tag with an affinity constant of 0.40 nM as determined in SPR assay (Biacore T200) (QC Test).
Biotinylated Human CD20 VLP captured on CM5 Chip via streptavidin can bind Ofatumumab, hFc Tag with an affinity constant of 0.22 nM as determined in SPR assay (Biacore T200).
B-lymphocyte antigen CD20 or CD20 is an activated-glycosylated phosphoprotein expressed on the surface of all B-cells beginning at the pro-B phase (CD45R , CD117) and progressively increasing in concentration until maturity.CD20 is the target of the monoclonal antibodies rituximab, ocrelizumab, obinutuzumab, ofatumumab, ibritumomab tiuxetan, tositumomab, and ublituximab, which are all active agents in the treatment of all B cell lymphomas, leukemias, and B cell-mediated autoimmune diseases.
MS4A1; CD20; MS4A-1; B1; Bp35; CD20 receptor; CD20S7; CVID5; LEU-16; Ly-44; MS4A2; S7
(1)Ma D , Mcdevitt M R , Barendswaard E , et al. Radioimmunotherapy for model B cell malignancies using 90Y-labeled anti-CD19 and anti-CD20 monoclonal antibodies[J]. Leukemia, 2002, 16(1):60-66. (2)Jager U , Fridrik M , Zeitlinger M , et al. Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response[J]. Haematologica, 2012, 97(9):1431-1438.
